These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 17378140)
21. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Tsimihodimos V; Dounousi E; Siamopoulos KC Am J Nephrol; 2008; 28(6):958-73. PubMed ID: 18612199 [TBL] [Abstract][Full Text] [Related]
22. [Statins: what is their place in the treatment of chronic kidney insufficiency?]. Ponte B; Bourquin V; Stoermann-Chopard C Rev Med Suisse; 2009 Feb; 5(192):463-4, 466-8. PubMed ID: 19317313 [TBL] [Abstract][Full Text] [Related]
23. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582 [TBL] [Abstract][Full Text] [Related]
24. Treatment and impact of dyslipidemia in diabetic nephropathy. Toyama T; Shimizu M; Furuichi K; Kaneko S; Wada T Clin Exp Nephrol; 2014 Apr; 18(2):201-5. PubMed ID: 24198049 [TBL] [Abstract][Full Text] [Related]
25. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. Zhou H; Tan KC; Shiu SW; Wong Y Nephrol Dial Transplant; 2008 Mar; 23(3):927-33. PubMed ID: 18065800 [TBL] [Abstract][Full Text] [Related]
26. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Raile K; Galler A; Hofer S; Herbst A; Dunstheimer D; Busch P; Holl RW Diabetes Care; 2007 Oct; 30(10):2523-8. PubMed ID: 17630266 [TBL] [Abstract][Full Text] [Related]
27. Association between apolipoprotein E genetic polymorphism and the development of diabetic nephropathy in type 2 diabetic patients. Kwon MK; Rhee SY; Chon S; Oh S; Woo JT; Kim SW; Kim JW; Kim YS; Jeong KH; Lee SH; Lee TW; Ihm CG Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S228-32. PubMed ID: 17624465 [TBL] [Abstract][Full Text] [Related]
28. [Secondary dyslipidemias and their treatment]. Soska V Vnitr Lek; 2007 Apr; 53(4):396-400. PubMed ID: 17578173 [TBL] [Abstract][Full Text] [Related]
29. Does coronary artery calcification in patients with diabetic nephropathy depend on the advancement of renal failure? Krzanowski M; Kuśnierz-Cabala B; Miarka P; Wójcik K; Stompór T; Sułowicz W Med Pregl; 2007; 60 Suppl 2():39-42. PubMed ID: 18928155 [TBL] [Abstract][Full Text] [Related]
30. Progression and remission of nephropathy in type 2 diabetes: new strategies of treatment and monitoring. Rossing K Dan Med Bull; 2007 May; 54(2):79-98. PubMed ID: 17521525 [No Abstract] [Full Text] [Related]
31. Concomitant macro and microvascular complications in diabetic nephropathy. Alwakeel JS; Al-Suwaida A; Isnani AC; Al-Harbi A; Alam A Saudi J Kidney Dis Transpl; 2009 May; 20(3):402-9. PubMed ID: 19414942 [TBL] [Abstract][Full Text] [Related]
32. Nonpharmacologic management of mixed dyslipidemia associated with diabetes mellitus and the metabolic syndrome: a review of the evidence. Stone NJ Am J Cardiol; 2008 Dec; 102(12A):14L-18L. PubMed ID: 19084085 [TBL] [Abstract][Full Text] [Related]
33. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia. Maciejewski S; Hilleman D Pharmacotherapy; 2008 May; 28(5):570-5. PubMed ID: 18447655 [TBL] [Abstract][Full Text] [Related]
34. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763 [TBL] [Abstract][Full Text] [Related]
35. Diabetic nephropathy and risk factors for peripheral artery disease in Chinese with type 2 diabetes mellitus. Hsieh MC; Tien KJ; Perng DS; Hsiao JY; Chang SJ; Liang HT; Chen HC; Tu ST Metabolism; 2009 Apr; 58(4):504-9. PubMed ID: 19303971 [TBL] [Abstract][Full Text] [Related]
36. Thailand diabetes registry project: current status of dyslipidemia in Thai diabetic patients. Pratipanawatr T; Rawdaree P; Chetthakul T; Bunnag P; Ngarmukos C; Benjasuratwong Y; Leelawatana R; Kosachunhanun N; Plengvidhya N; Deerochanawong C; Suwanwalaikorn S; Krittiyawong S; Mongkolsomlit S; Komoltri C J Med Assoc Thai; 2006 Aug; 89 Suppl 1():S60-5. PubMed ID: 17715835 [TBL] [Abstract][Full Text] [Related]
37. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Fazio S Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268 [TBL] [Abstract][Full Text] [Related]
38. Ezetimibe in heart transplantation: initial experience. Moro J; Almenar L; Martínez-Dolz L; Izquierdo M; Agüero J; Sánchez-Lazaro I; Ortiz V; Salvador A Transplant Proc; 2007 Sep; 39(7):2389-92. PubMed ID: 17889199 [TBL] [Abstract][Full Text] [Related]
39. Dyslipidemia therapy update: the importance of full lipid profile assessment. Menown IB; Murtagh G; Maher V; Cooney MT; Graham IM; Tomkin G Adv Ther; 2009 Jul; 26(7):711-8. PubMed ID: 19649582 [TBL] [Abstract][Full Text] [Related]
40. Effects of pioglitazone on lipid and lipoprotein metabolism. Betteridge DJ Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]